Authors: T K Lauridsen L E Bruun R V Rasmussen M Arpi N Risum C Moser H K Johansen H Bundgaard C Hassager N E Bruun
Publish Date: 2012/03/20
Volume: 31, Issue: 10, Pages: 2567-2574
Abstract
The increasing number of resistant bacterial strains in infective endocarditis IE emphasizes the need for a constant development of antimicrobials Linezolid is an oxazolidinone with an effect on Grampositive cocci Only a few casuistic reports describe its utilization in the treatment of IE The objective of this study is to report our experience with linezolid from a large consecutive cohort of IE patients In a retrospective cohort study data on 550 consecutive IE patients were collected at two tertiary University Hospitals in Copenhagen Denmark The main endpoints were differences in the inhospital and 12 months postdischarge mortality between IE patients receiving linezolid for a part of the treatment and IE patients receiving conventional treatment Of the 550 patients enrolled in the study 38 patients received linezolid treatment and 512 received conventional treatment Reasons for adding linezolid were antibiotic intolerance n = 13 nephrotoxicity n = 5 pharmaceutical interactions n = 1 inadequate clinical response n = 14 or inadequate microbial response n = 5 No significant differences in the cure rate 74 vs 71 p 005 inhospital mortality 13 vs 14 p 005 or postdischarge mortality at 12 months followup 26 vs 26 p 005 were observed In the current study we found that linezolid in general was well tolerated and associated with the same outcome as in patients with Grampositive IE treated with other antibiotics
Keywords: